Numerous studies, on the role of reactive oxygen species (ROS), as one of the risk factors, which simultaneously reduce the activity of antioxidant factors in the progression atherosclerosis, cardiovascular disorders (CVD) and end stage renal disease (ESRD), has been conducted (
1-
3). Hemodialysis (HD) is the most common method used to treat advanced and permanent kidney failure. The mortality and morbidity risks of long-term HD can be relevant to several factors like protein wasting, inflammation, impaired immune responsiveness and, especially, oxidative stress (
4). The oxidative stress results from an imbalance between oxidants or pro-oxidants production and antioxidant defense mechanisms (
5). Antioxidants can be divided into intracellular and extracellular antioxidants. Intracellular enzymatic antioxidants are superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GpX), which convert specific substrates to less reactive compounds (
3). Extracellular antioxidants, such as albumin, bilirubin and uric acid prevent free radical reaction by collecting pro-oxidants or chelating transition metal ions (
6). The ROS, such as the superoxide anion, hydrogen peroxide and hydroxyl radical that are produced massively in oxidative stress conditions, cause depletion of sulfhydryl (-SH) groups and oxidation of multiple molecules, such as membrane lipids, protein and nucleic acid molecules, in the human body, that can cause tissue damage (
5,
7,
8). There is a range of defense mechanisms to keep cells from oxidative damage. These include the factors that limit the production of ROS, scavenging of radicals that are formed to prevent the production of secondary radicals in chain reactions and to repair the damage that may however occur (
7). Although several studies have suggested an alteration of the oxidative stress phenomenon, by production of ROS on the surface of dialysis membranes, by activation of polymorphonuclear leukocytes in patients undergoing HD (
9-
11), there are limited reports about the correlation between the status of total antioxidant capacity (TAC) of plasma and their associated components and lipid peroxidation products.